Research: Monitoring the Effect of Nivolumab in Non-Small Cell Lung Cancer
Researchers all over the world are dedicatedly working towards improving survival rates of lung cancer patients. Now, the researchers from Osaka University have found a new method for monitoring the effect of lung cancer therapy. Dr. Tasuku Honjo, the winner of 2018 Nobel Prize in Physiology or Medicine, has discovered immune T-cell protein PD-1. This discovery led to formation of anti-cancer medications and one of them was nivolumab or Opdivo. The researchers have developed a simple way to test the effects of nivolumab in the body. Their method evaluates how nivolumab binds to PD-1 on T-cells after the treatment. They analyzed tiny samples of blood and lung fluid from the lung cancer patients. Then, the researchers measured the amount of nivolumab bound to T-cells and isolated the ones bound by nivolumab. The effects of nivolumab existed in patients for a considerable amount of time. The findings by the team confirmed that the level of T-cell binding is not an indicator of the